ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Increasing Levels of von Willebrand Factor (VWF) and Factor VIII (FVIII:C) with Age in Patients Affected by von Willebrand Disease (VWD)

E. Biguzzi1,2, S.M. Siboni3, S. Le Cessie2, L. Baronciani3, F.R. Rosendaal2, A. van Hylckama Vlieg2, F. Peyvandi4,5

1Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy, 2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands, 3Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy, 4Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy, 5Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milano, Italy

Abstract Number: PB1578

Meeting: ISTH 2020 Congress

Theme: Platelet Disorders and von Willebrand Disease » VWF and von Willebrand Factor Disorders - Clinical Conditions

Background: Increasing levels of von Willebrand Factor (VWF) and factor VIII (FVIII:C) were associated with age in patients affected by VWD type 1.

Aims: To evaluate the increase of FVIII:C and VWF with age in a large group of patients affected by VWD, in whom levels were repeatedly measured.

Methods: Clinical charts from all patients evaluated at the A. Bianchi Bonomi Hemophilia and Thrombosis Center between 1970 and 2018 were reviewed and data on VWF, FVIII:C, cancer, diabetes, hypertension collected. VWF activity was measured with 4 different assays depending on the date of the assay (VWF:Rco, measured by aggregometry, and subsequently with an automated coagulometer; VWF:Ab, and VWF:GpIbR). FVIII:C was measured by one-stage assay. The repeated measurements were evaluated by linear mixed effects models, adjusting for age at first measurement, sex, blood group (O or non-O), presence of comorbidities, and type of test for VWF activity.

Results: . In total 714 patients were included (23 excluded for missing data and 11 for VWD affecting only collagen binding or RIPA assays): 39 (5%) were affected by VWD type 3 or severe type 1, 314 (44%) by type 2, 293 (41%) by type 1 or 1 Vicenza, 68 by others (2N, not classified, type 3 carriers, type 2N carriers). Repeated measurements were available for 429 (60%) patients (172 type 1 and 211 type 2) for a total of 2844 tests. After adjustments, VWF activity and FVIII:C were positively associated with age (1.81 IU/dL and 2.86 IU/dL increase per decade respectively). Stratification on VWD type confirmed the increment of VWF activity in type 1 and of FVIII:C in type 1 and type 2 patients.

Conclusions: Our results indicate a mild increase of FVIII with age in patients with VWD. Only patients affected by type 1 VWD show a mild increase of VWF activity with age.

  All (N=714) Type 1 (N=293) Type 2 (N=314)
Sex female,
n (%)
412 (58) 185 (63) 163 (52)
Blood group 0,
n (%), missing
296 (61), 229 153 (72), 81 109 (53), 107
Age at first measurement, years
median, IQ range), missing
28 (13-42), 1 27 (16-39), 2 28 (11-46), 1
VWF activity at 1st measurement, IU/dL
median (IQ range), missing
21 (6-40), 19 35 (20-44), 5 9 (3-22), 8
FVIII:C at 1st measurement, IU/dL
median (IQ range), missing
53 (37-70), 19 58 (44-72), 5 49 (37-64), 10
Time between first and last measurement, years
median (IQ range), missing
15 (6-24), 1 15 (7-21) 15 (7-25), 1
Number of repeated measurements,
median (IQ range)
3 (1-6) 2 (1-5) 3 (1-7)
Comorbidities (cancer, diabetes, high blood pressure)
n (%), missing
21 (5), 287 6 (3.5), 121 13 (6), 105

[Table 1. Clinical characteristics.]

  All patients
(N=714)
Type 1
(N=293)
Type 2
(N=314)
VWF activity, IU/dL      
Crude Beta coefficient per decade (95%CI) 2.24
(1.63-2.84)
2.67
(1.67-3.66)
1.30
(0.64-1.97)
Adjusted# Beta coefficient per decade (95%CI) 1.81
(0.33-3.28)
5.13
(2.70-7.56)
-0.040
(-2.13-1.33)
FVIII:C, IU/dL      
Crude Beta coefficient per decade (95%CI) 2.50
(1.68-3.33)
2.14
(0.77-3.52)
2.18
(1.16-3.20)
Adjusted# Beta coefficient per decade (95%CI) 2.86
(1.66-4.06)
2.94
(1.08-4.79)
3.84
(2.25-5.44)
# adjusted for age at first measurement, sex, blood group, cancer, diabetes, hypertension (and test type for VWF).

[Table 2. Increment of VWF:activity and FVIII:C with age.]

To cite this abstract in AMA style:

Biguzzi E, Siboni SM, Le Cessie S, Baronciani L, Rosendaal FR, van Hylckama Vlieg A, Peyvandi F. Increasing Levels of von Willebrand Factor (VWF) and Factor VIII (FVIII:C) with Age in Patients Affected by von Willebrand Disease (VWD) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/increasing-levels-of-von-willebrand-factor-vwf-and-factor-viii-fviiic-with-age-in-patients-affected-by-von-willebrand-disease-vwd/. Accessed September 29, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/increasing-levels-of-von-willebrand-factor-vwf-and-factor-viii-fviiic-with-age-in-patients-affected-by-von-willebrand-disease-vwd/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley